Share This Page
Drug Price Trends for FT ADULT TUSSIN
✉ Email this page to a colleague
Average Pharmacy Cost for FT ADULT TUSSIN
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FT ADULT TUSSIN 200 MG/10 ML | 70677-1186-01 | 0.02236 | ML | 2026-05-20 |
| FT ADULT TUSSIN 200 MG/10 ML | 70677-1186-02 | 0.01815 | ML | 2026-05-20 |
| FT ADULT TUSSIN 200 MG/10 ML | 70677-1186-01 | 0.02242 | ML | 2026-04-22 |
| FT ADULT TUSSIN 200 MG/10 ML | 70677-1186-02 | 0.01813 | ML | 2026-04-22 |
| FT ADULT TUSSIN 200 MG/10 ML | 70677-1186-02 | 0.01813 | ML | 2026-03-18 |
| FT ADULT TUSSIN 200 MG/10 ML | 70677-1186-01 | 0.02235 | ML | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for FT Adult Tussin
What is FT Adult Tussin?
FT Adult Tussin is an over-the-counter (OTC) cough and cold medication primarily used for symptomatic relief of cough, congestion, and cold symptoms in adults. It combines active ingredients such as dextromethorphan, guaifenesin, and phenylephrine. Marketed by a major pharmaceutical company, the product is available through retail pharmacy channels, mass merchandisers, and e-commerce platforms.
Market Landscape
Industry Overview
The global cough and cold remedy market was valued at approximately USD 7 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% over the next five years. North America accounts for 50% of market revenue, driven by high OTC drug penetration and consumer health awareness.
Competitive Position
FT Adult Tussin faces competition from both branded OTC products and generic formulations. Major competitors include:
- Mucinex (Reckitt Benckiser)
- Robitussin (Johnson & Johnson)
- Delsym (Adams Respiratory Therapeutics)
- Store brands (private label generics)
Market share for FT Adult Tussin remains estimated at 8-10% within the adult OTC cough and cold segment, which is driven by brand recognition and physician recommendations.
Regulatory Environment
The product is classified as OTC, approved by the Food and Drug Administration (FDA), with active ingredients meeting monograph standards. No recent regulatory changes directly affect its market access; however, ongoing monitoring of ingredient safety profiles remains vital.
Market Trends and Drivers
- An aging population increases demand due to higher prevalence of respiratory illnesses.
- The COVID-19 pandemic heightened consumer focus on OTC cold remedies.
- Rising awareness of self-care products among consumers propels sales.
- Trends toward natural and organic ingredients challenge traditional formulations but have limited impact on FT Adult Tussin's market share.
Pricing Analysis
Current Price Positioning
- Retail price per 4 oz (118 mL) bottle ranges from USD 8 to USD 12.
- Price elasticity suggests a 10-15% sensitivity for consumers based on price changes.
- Store brands are priced approximately 10-20% lower than branded FT Adult Tussin, influencing consumer choice.
Pricing Strategy Factors
- Brand loyalty sustains premium pricing.
- Contractual agreements with retail chains impact wholesale prices.
- Promotional discounts and bundling tactics reduce effective consumer prices.
Price Projection
Short-Term (Next 12 months)
- Anticipate slight price stabilization with minimal variation, assuming no inflationary cost increases.
- Wholesale prices are expected to remain around USD 6.50 to USD 7.50 per 4 oz bottle, influenced by competitive pressures, especially from generics.
Medium-Term (1-3 years)
- Slight upward pressure of 2-4% annually, driven by rising raw material costs (e.g., dextromethorphan, phenylephrine).
- Potential price adjustments due to supply chain disruptions or regulatory shifts, though none currently forecasted.
Long-Term (3-5 years)
- Prices could reach USD 9 to USD 13 per bottle assuming inflation, increased manufacturing costs, and sustained demand.
- Competitive entry of natural or alternative remedies could pressure prices downward or force innovation.
Key Market Risks
- Regulatory changes affecting active ingredients could reduce formulation flexibility.
- Increased competition from generic brands could compress margins.
- Supply chain disruptions, especially for raw materials, may lead to price volatility.
Investment and R&D Implications
- No imminent patent protections expire; the product maintains market exclusivity.
- R&D focus is on novel formulations or delivery systems, which could redefine competitive dynamics.
- Marketing strategies emphasizing efficacy and trusted brand status remain critical.
Summary of Price Forecasts
| Time Frame | Price Range (USD) per 4 oz bottle) | Drivers | Risks |
|---|---|---|---|
| 0-1 year | USD 8-12 | Stable supply, moderate promotional activity | Competition from generics, inflation |
| 1-3 years | USD 8.16-12.48 | Raw material cost increases, demand stability | Regulatory shifts, market saturation |
| 3-5 years | USD 9-13 | Inflation, market growth, innovation impact | Market entry of alternative therapies |
Key Takeaways
- FT Adult Tussin holds an 8-10% share in the OTC adult cough and cold segment.
- The market is expected to grow modestly, with pricing projections increasing 2-4% annually.
- Competitive pressures and supply chain factors will influence future price movements.
- The product’s brand strength and regulatory compliance support current pricing stability.
- Long-term prospects depend on innovation and market dynamics, including consumer preferences for natural remedies.
FAQs
Q1: How does FT Adult Tussin differentiate from competitors?
A: Brand recognition, proven efficacy, and consumer trust are key differentiators. Formulation stability and comprehensive marketing support maintain its competitive edge.
Q2: What external factors could impact price projections?
A: Raw material cost fluctuations, regulatory changes, and shifts in consumer preferences toward natural products can influence pricing.
Q3: How significant is the generic competition?
A: Generics currently capture 60-70% of the OTC cough and cold market, exerting pressure on pricing and margins.
Q4: What strategies could improve market share?
A: Innovation in delivery systems, expanding into new geographic markets, and targeted marketing campaigns can enhance competitive positioning.
Q5: Are supply chain disruptions a concern?
A: Yes. Global supply constraints for key ingredients or packaging materials could lead to price volatility and availability issues.
References
- Grand View Research. (2022). Cough & Cold Remedy Market Size, Share & Trends Analysis Report.
- U.S. Food and Drug Administration. (2022). OTC Drug Review - Monographs.
- Statista. (2022). OTC Cough and Cold Remedies Market Overview.
- IBISWorld. (2022). OTC Medicine Manufacturing.
- MarketsandMarkets. (2022). Consumer Healthcare Market Growth and Forecast.
More… ↓
